tradingkey.logo

Biontech SE

BNTX
View Detailed Chart

106.570USD

+1.650+1.57%
Close 06/13, 16:00ETQuotes delayed by 15 min
25.62BMarket Cap
LossP/E TTM

Biontech SE

106.570

+1.650+1.57%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.57%

5 Days

-1.77%

1 Month

+15.73%

6 Months

-11.47%

Year to Date

-6.48%

1 Year

+15.74%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 22 analysts
BUY
Current Rating
134.305
Target Price
26.03%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

557
Total
5
Median
6
Average
Company name
Ratings
Analysts
Biontech SE
BNTX
22
Exact Sciences Corp
EXAS
28
CRISPR Therapeutics AG
CRSP
28
Regeneron Pharmaceuticals Inc
REGN
28
Intellia Therapeutics Inc
NTLA
28
Moderna Inc
MRNA
26
1
2
3
...
112

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Neutral
Sell(5)
Neutral(2)
Buy(6)
Indicators
Sell(3)
Neutral(2)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.105
Buy
RSI(14)
54.254
Neutral
STOCH(KDJ)(9,3,3)
19.338
Sell
ATR(14)
5.151
High Vlolatility
CCI(14)
1.430
Neutral
Williams %R
55.544
Sell
TRIX(12,20)
0.439
Sell
StochRSI(14)
38.520
Buy
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
106.562
Buy
MA10
109.134
Sell
MA20
103.630
Buy
MA50
100.481
Buy
MA100
105.203
Buy
MA200
108.782
Sell

News

More news coming soon, stay tuned...

Company

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Ticker SymbolBNTX
CompanyBiontech SE
CEOProf. Ugur Sahin, M.D.
Websitehttps://www.biontech.com/
KeyAI